Awachana Jiamsakul1, Azar Kariminia, Keri N Althoff, Carina Cesar, Claudia P Cortes, Mary-Ann Davies, Viet Chau Do, Brian Eley, John Gill, Nagalingeswaran Kumarasamy, Daisy Maria Machado, Richard Moore, Hans Prozesky, Elizabeth Zaniewski, Matthew Law. 1. *The Kirby Institute, UNSW, Sydney, New South Wales, Australia; †Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; ‡Fundacion Huesped, Buenos Aires, Argentina; §University of Chile School of Medicine & Fundación Arriaran, Santiago, Chile; ‖School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa; ¶Children's Hospital 2, Ho Chi Minh City, Vietnam; #Department of Paediatrics and Child Health, University of Cape Town, Cape Town, South Africa; **University of Calgary, Calgary, Alberta, Canada; ††YRGCARE Medical Centre, Chennai, India; ‡‡Pediatric Infectious Disease Division, Escola Paulista de Medicina-Universidade Federal de SãoPaulo, São Paulo, Brazil; §§Division of Infectious Diseases, Department of Medicine, Johns Hopkins University, Baltimore, MD; ‖‖Division of Infectious Diseases, Department of Medicine, University of Stellenbosch and Tygerberg Hospital, Cape Town, South Africa; and ¶¶Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
Abstract
BACKGROUND: Having 90% of patients on antiretroviral therapy (ART) and achieving an undetectable viral load (VL) is 1 of the 90:90:90 by 2020 targets. In this global analysis, we investigated the proportions of adult and paediatric patients with VL suppression in the first 3 years after ART initiation. METHODS: Patients from the IeDEA cohorts who initiated ART between 2010 and 2014 were included. Proportions with VL suppression (<1000 copies/mL) were estimated using (1) strict intention to treat (ITT)-loss to follow-up (LTFU) and dead patients counted as having detectable VL; and (2) modified ITT-LTFU and dead patients were excluded. Logistic regression was used to identify predictors of viral suppression at 1 year after ART initiation using modified ITT. RESULTS: A total of 35,561 adults from 38 sites/16 countries and 2601 children from 18 sites/6 countries were included. When comparing strict with modified ITT methods, the proportion achieving VL suppression at 3 years from ART initiation changed from 45.1% to 90.2% in adults, and 60.6% to 80.4% in children. In adults, older age, higher CD4 count pre-ART, and homosexual/bisexual HIV exposure were associated with VL suppression. In children, older age and higher CD4 percentage pre-ART showed significant associations with VL suppression. CONCLUSIONS: Large increases in the proportion of VL suppression in adults were observed when we excluded those who were LTFU or had died. The increases were less pronounced in children. Greater emphasis should be made to minimize LTFU and maximize patient retention in HIV-infected patients of all age groups.
BACKGROUND: Having 90% of patients on antiretroviral therapy (ART) and achieving an undetectable viral load (VL) is 1 of the 90:90:90 by 2020 targets. In this global analysis, we investigated the proportions of adult and paediatric patients with VL suppression in the first 3 years after ART initiation. METHODS:Patients from the IeDEA cohorts who initiated ART between 2010 and 2014 were included. Proportions with VL suppression (<1000 copies/mL) were estimated using (1) strict intention to treat (ITT)-loss to follow-up (LTFU) and dead patients counted as having detectable VL; and (2) modified ITT-LTFU and dead patients were excluded. Logistic regression was used to identify predictors of viral suppression at 1 year after ART initiation using modified ITT. RESULTS: A total of 35,561 adults from 38 sites/16 countries and 2601 children from 18 sites/6 countries were included. When comparing strict with modified ITT methods, the proportion achieving VL suppression at 3 years from ART initiation changed from 45.1% to 90.2% in adults, and 60.6% to 80.4% in children. In adults, older age, higher CD4 count pre-ART, and homosexual/bisexual HIV exposure were associated with VL suppression. In children, older age and higher CD4 percentage pre-ART showed significant associations with VL suppression. CONCLUSIONS: Large increases in the proportion of VL suppression in adults were observed when we excluded those who were LTFU or had died. The increases were less pronounced in children. Greater emphasis should be made to minimize LTFU and maximize patient retention in HIV-infectedpatients of all age groups.
Authors: A Cozzi-Lepri; A N Phillips; B Clotet; J Kjaer; V Von Wyl; G Kronborg; A Castagna; J R Bogner; J D Lundgren Journal: HIV Med Date: 2011-08-17 Impact factor: 3.180
Authors: Steven J Reynolds; Gertrude Nakigozi; Kevin Newell; Anthony Ndyanabo; Ronald Galiwongo; Iga Boaz; Thomas C Quinn; Ron Gray; Maria Wawer; David Serwadda Journal: AIDS Date: 2009-03-27 Impact factor: 4.177
Authors: Shirley Lecher; Dennis Ellenberger; Andrea A Kim; Peter N Fonjungo; Simon Agolory; Marie Yolande Borget; Laura Broyles; Sergio Carmona; Geoffrey Chipungu; Kevin M De Cock; Varough Deyde; Marie Downer; Sundeep Gupta; Jonathan E Kaplan; Charles Kiyaga; Nancy Knight; William MacLeod; Boniface Makumbi; Hellen Muttai; Christina Mwangi; Jane W Mwangi; Michael Mwasekaga; Lucy W Ng'Ang'A; Yogan Pillay; Abdoulaye Sarr; Souleymane Sawadogo; Daniel Singer; Wendy Stevens; Christiane Adje Toure; John Nkengasong Journal: MMWR Morb Mortal Wkly Rep Date: 2015-11-27 Impact factor: 17.586
Authors: Keri N Althoff; Peter F Rebeiro; David B Hanna; Denis Padgett; Michael A Horberg; Beatriz Grinsztejn; Alison G Abraham; Robert Hogg; M John Gill; Marcelo J Wolff; Angel Mayor; Anita Rachlis; Carolyn Williams; Timothy R Sterling; Mari M Kitahata; Kate Buchacz; Jennifer E Thorne; Carina Cesar; Fernando M Cordero; Sean B Rourke; Juan Sierra-Madero; Jean W Pape; Pedro Cahn; Catherine McGowan Journal: J Int AIDS Soc Date: 2016-04-04 Impact factor: 5.396
Authors: Jean B Nachega; Nadia A Sam-Agudu; Lynne M Mofenson; Mauro Schechter; John W Mellors Journal: Clin Infect Dis Date: 2018-05-02 Impact factor: 9.079
Authors: A Jiamsakul; S Kiertiburanakul; O T Ng; R Chaiwarith; W Wong; R Ditangco; K V Nguyen; A Avihingsanon; S Pujari; C D Do; M-P Lee; P S Ly; E Yunihastuti; N Kumarasamy; A Kamarulzaman; J Tanuma; F Zhang; J Y Choi; P Kantipong; Blh Sim; J Ross; M Law; T P Merati Journal: HIV Med Date: 2019-04-12 Impact factor: 3.180
Authors: Paul Y Wada; Ahra Kim; Karu Jayathilake; Stephany N Duda; Yao Abo; Keri N Althoff; Morna Cornell; Beverly Musick; Steve Brown; Annette H Sohn; Yu Jiun Chan; Kara K Wools-Kaloustian; Denis Nash; Constantin T Yiannoutsos; Carina Cesar; Catherine C McGowan; Peter F Rebeiro Journal: AIDS Patient Care STDS Date: 2022-08-26 Impact factor: 5.944
Authors: Isaac Tsikhutsu; Margaret Bii; Nicole Dear; Kavitha Ganesan; Alex Kasembeli; Valentine Sing'oei; Kevin Rombosia; Christopher Ochieng; Priyanka Desai; Vanessa Wolfman; Peter Coakley; Elizabeth H Lee; Patrick W Hickey; Jeffrey Livezey; Patricia Agaba Journal: Clin Infect Dis Date: 2022-09-29 Impact factor: 20.999
Authors: Win Min Han; Matthew G Law; Matthias Egger; Kara Wools-Kaloustian; Richard Moore; Catherine McGowan; Nagalingesawaran Kumarasamy; Sophie Desmonde; Andrew Edmonds; Mary-Ann Davies; Constantin Yiannoutsos; Keri N Althoff; Claudia P Cortes; Thahira Jamal Mohamed; Antoine Jaquet; Kathryn Anastos; Jonathan Euvrard; Barbara Castelnuovo; Kate Salters; Lara Esteves Coelho; Didier K Ekouevi; Brian Eley; Lameck Diero; Elizabeth Zaniewski; Nathan Ford; Annette H Sohn; Azar Kariminia Journal: Lancet HIV Date: 2021-12 Impact factor: 16.070
Authors: M Kate Grabowski; Eshan U Patel; Gertrude Nakigozi; Victor Ssempijja; Robert Ssekubugu; Joseph Ssekasanvu; Anthony Ndyanabo; Godfrey Kigozi; Fred Nalugoda; Ronald H Gray; Sarah Kalibbala; David M Serwadda; Oliver Laeyendecker; Maria J Wawer; Larry W Chang; Thomas C Quinn; Joseph Kagaayi; Aaron A R Tobian; Steven J Reynolds Journal: J Infect Dis Date: 2021-04-08 Impact factor: 7.759